Kunxian capsule alleviates podocyte injury and proteinuria by inactivating β-catenin in db/db mice

BACKGROUND: Diabetic kidney disease (DKD) remains the primary cause of end-stage renal disease (ESRD) globally, but treatment options are limited. Kunxian capsule (KXC) has been utilized for the treatment of autoimmune diseases and IgA nephropathy in China. However, its effect on DKD remains poorly...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Bo, Liu, Jing, Zhu, Yan, Lu, Jian, Zhang, Qingyan, Liang, Yan, Shao, Qiuyuan, Jiang, Chunming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349331/
https://www.ncbi.nlm.nih.gov/pubmed/37457567
http://dx.doi.org/10.3389/fmed.2023.1213191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349331/
https://www.ncbi.nlm.nih.gov/pubmed/37457567
http://dx.doi.org/10.3389/fmed.2023.1213191

Ejemplares similares